EN DE
Watch Qomel Company Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Qomel Company Limited (9600) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Qomel Company Limited stock SAR 46.13, price SAR 34.00, upside +35.7%, quality 27 out of 100. Rating: undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SA · ISIN SA162184M018

QC Qomel Company Limited logo Some data Nov 15, 2026

Qomel Company Limited

9600 · SR

Cheap (26% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value 46.13 SAR · Undervalued 
Low debt 
Expensive Growth (revenue 3y +19.4 %/yr in SAR) 
Thin margins · 5.3% net margin (TTM) 
Some data 
Revenue last quarter 8% below a year ago. 
Changed on Oct 23: SAR 38.02 → SAR 46.13 
Quality 27/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (4/12) 
Narrow moat 39/100 · thin data
Watch Qomel Company Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

67.50 SAR 29.80 SAR Fair Value 46.13 SAR May 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

30‑month range 29.80 SAR – 67.50 SAR · fair‑value band 33.97 SAR – 58.29 SAR · the 34.00 SAR price screens below the 46.13 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Qomel Company in your weekly email

Every Wednesday you see whether Qomel Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Qomel Company Limited operates as a healthcare company in Saudi Arabia. The company is involved in the sale of medicine and natural medicinal herbs. It also offers pharmaceutical and medical supplies services. The company was founded in 2007 and is headquartered in Riyadh, Saudi Arabia.

Stock analysis

Qomel Company Limited (9600) currently trades at 34.00 SAR, while our model-based Fair Value estimate is 46.13 SAR, implying the stock looks roughly 26% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 54.72 SAR per share, and 10 of the 14 models we run sit above the 34.00 SAR price.

Bear case: the Asset-Based group reads lowest at 4.93 SAR, and 4 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 33.97 SAR (bear) to 58.29 SAR (bull), the price of 34.00 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Qomel Company Limited reported revenue of 132M SAR in FY2025 versus 61.2M SAR in FY2021, a compound +21.2%/yr. Reported net income was 15.0M SAR in FY2025, compounding +25.0%/yr from FY2021.

Key figures

Market cap 238M SAR (≈ $63.3M) Micro · P/E ratio 22.8 · P/S ratio 2.58 · EPS (TTM) 1.49 SAR · Net margin 11.3% · Return on equity 5.6% · Return on assets (EBIT) 16.6% (5-year average) · Operating margin 8.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 25% fair-value upside, at 36%, 9600 screens cheaper than that median.

Fair Value models

Bear 33.97 SAR Fair Value 46.13 SAR Bull 58.29 SAR
Price 34.00 SAR · Upside +35.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (1.31 SAR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 18.91 SAR 21.33 SAR 23.31 SAR 74
ROIC Compounder 19.92 SAR 25.93 SAR 31.51 SAR 69
Residual Income 14.68 SAR 16.46 SAR 20.86 SAR 68
All 14 models by family
Earnings-Based
Graham-Dodd 14.53 SAR 91.22 SAR 127.42 SAR 61
Lynch FV 26.30 SAR 37.57 SAR 48.84 SAR 58
PEG = 1.0 26.30 SAR 37.57 SAR 48.84 SAR 55
EPV 18.91 SAR 21.33 SAR 23.31 SAR 74
Multiples
P/E Multiple 35.26 SAR 47.01 SAR 58.76 SAR 63
P/S Multiple 27.24 SAR 36.33 SAR 45.41 SAR 58
P/B Multiple 57.77 SAR 77.03 SAR 96.28 SAR 55
EV/EBIT 33.97 SAR 46.13 SAR 58.29 SAR 66
EV/EBITDA 27.89 SAR 38.02 SAR 48.16 SAR 67
EV/Revenue 23.52 SAR 34.68 SAR 45.85 SAR 53
Asset-Based
NCAV (Graham) 3.25 SAR 4.93 SAR 6.16 SAR 54
Economic Profit
Residual Income 14.68 SAR 16.46 SAR 20.86 SAR 68
ROIC Compounder 19.92 SAR 25.93 SAR 31.51 SAR 69
Growth Earnings
Growth-Adj P/E 38.30 SAR 54.72 SAR 71.13 SAR 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 13
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+3.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%

Watch 9600, get fair value alerts →

Compare Qomel Company Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 52 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +35.7% · Above median
Profitability
Return on equity (12 months) 5.6% · Below median
Return on assets 6.8% · Top 25%
Net margin (12 months) 5.3% · Top 25%
Operating margin (12 months) 8.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −8.1% · Bottom 25%
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (12 months) 22.8× · Pricier than median
P/B 1.98× · Pricier than median
P/S (12 months) 1.88× · Priciest 25%
EV/EBITDA 19.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)81 · sector 63
FUTURE (revenue growth)0 · sector 19
PAST (return on equity)23 · sector 25
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 55

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Qomel Company Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Qomel Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/9600

Frequently asked questions

Is Qomel Company Limited (9600) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 46.13 SAR versus a price of 34.00 SAR, about +36% upside (undervalued).
What is the fair value of 9600?
Our model-based fair value for Qomel Company Limited is 46.13 SAR (as of Nov 15, 2026), built from audited fundamentals. The current price: 34.00 SAR.
What is the quality score of 9600?
Qomel Company Limited has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qomel Company Limited (9600)?
Our model-based price target is the fair value of 46.13 SAR (as of Nov 15, 2026) from 14 valuation models. Cautious scenario 33.97 SAR, optimistic scenario 58.29 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Qomel Company Limited stock forecast for 2026?
Our models put fair value at 46.13 SAR, about +36% upside versus a price of 34.00 SAR (undervalued). Cautious scenario 33.97 SAR, optimistic scenario 58.29 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Qomel Company Limited (9600)?
Qomel Company Limited reported trailing-twelve-month revenue of about 126M SAR (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Qomel Company Limited (9600)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qomel Company Limited it is 46.13 SAR per share (as of Nov 15, 2026), against a price of 34.00 SAR. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Qomel Company Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 9600 trades below its calculated fair value: price 34.00 SAR, fair value 46.13 SAR, a gap of about +36% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9600?
No. The price is what the market pays today (34.00 SAR); the fair value is what the company's own numbers justify (46.13 SAR). For Qomel Company Limited the two are 12.13 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Qomel Company Limited worth?
The market values Qomel Company Limited at about 238M SAR (market capitalisation, as of Nov 15, 2026). Per share that is 34.00 SAR; our models calculate a fair value of 46.13 SAR per share.
What do the bullish and bearish scenarios say about 9600?
Our models span a range for Qomel Company Limited: cautious scenario 33.97 SAR, base 46.13 SAR, optimistic 58.29 SAR per share (as of Nov 15, 2026, price 34.00 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9600?
Qomel Company Limited trades at a price-to-earnings ratio of 22.8 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 46.13 SAR is built from several models across several years. Other multiples: P/B 2.0, P/S 1.9, EV/EBITDA 19.0.
How solid is the balance sheet of Qomel Company Limited (9600)?
Balance-sheet figures for Qomel Company Limited (as of Nov 15, 2026): return on equity 5.6%, debt of 0.19 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 9600 from its 52-week high?
Qomel Company Limited trades at 34.00 SAR, about 43% below its 52-week high of 59.25 SAR and 14% above the low of 29.80 SAR (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of 46.13 SAR is for.
Which stocks are comparable to Qomel Company Limited?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qomel Company Limited stock attractive at the current price?
The data as of Nov 15, 2026: price 34.00 SAR, calculated fair value 46.13 SAR (+36%), Quality Score 27/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9600 calculated?
We run Qomel Company Limited through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 46.13 SAR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Qomel Company Limited currently trades 26% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qomel Company Limited (9600)?
The closing price on Nov 12, 2026 was 34.00 SAR. Our model-based fair value is 46.13 SAR, about +36% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qomel Company Limited right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Qomel Company Limited

How large is the market capitalisation of Qomel Company Limited (9600)?
The market capitalisation of Qomel Company Limited is 238M SAR (≈ $63.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qomel Company Limited (9600)?
The price-to-sales ratio of Qomel Company Limited is 2.58 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qomel Company Limited (9600)?
Earnings per share at Qomel Company Limited are 1.49 SAR (price ÷ EPS = P/E 22.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Qomel Company Limited (9600)?
The net margin of Qomel Company Limited is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qomel Company Limited (9600)?
The return on equity (ROE) of Qomel Company Limited is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qomel Company Limited (9600)?
On an EBIT basis the return on assets of Qomel Company Limited is 16.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qomel Company Limited (9600)?
The operating margin of Qomel Company Limited is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qomel Company Limited (9600)?
Revenue at Qomel Company Limited is down 8.1% versus a year earlier (3y avg +19.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qomel Company Limited (9600)?
Earnings per share at Qomel Company Limited are down 69.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Qomel Company Limited (9600) generate?
The free cash flow of Qomel Company Limited is −25.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Qomel Company Limited (9600) carry?
The net debt of Qomel Company Limited is 17.7M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Qomel Company Limited in the live analysis

One click puts Qomel Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.